Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The behaviour in vivo of tight and loose variants of murine melanoma cells is further characterized. In vitro clonal morphology is reproduced on a variety of substrates. Results suggest that repeated selection of loose cells can co-select for cells with high metastatic and colonization potentials. Measurement of cell motility shows that 1G3 (loose) cells are more motile than 1G8 (tight) which are restricted to movements within clonal boundaries. Studies of adhesive properties show that loose cells are more easily detached from the substrate with trypsin or EDTA and that both cell lines attach more quickly to monolayers of loose cells than to tight ones. No gross differences are found either in attachment rates to plastic and ECM or in aggregation and disaggregation rates. Analysis of the cell surface has not revealed any differences between 1G8 and 1G3 in the sialylation of terminal galactose and N-acetylgalactosamine residues or in neuraminidase releasable sialic acid. The binding patterns of iodinated lectins to SDS-PAGE separated proteins are similar for both lines except for one 85/90 KD protein which is more abundant in 1G3 than 1G8 cells after neuraminidase treatment. The results show enhanced differences in metastatic potential of tight and loose clones after selective cloning and that there may be important differences in motility and cell-substrate interactions.
 ...
PMID:Morphological and metastatic murine melanoma variants: motility, adhesiveness, cell surface and in vivo properties. 342 20

B16-F1 melanoma cells cultivated in vitro as spheroids on a non-adhesive substrate acquire in a reversible fashion an increase in lung colonization in vivo as compared to cells cultured as a monolayer. After neuraminidase treatment of protein blots, the spheroidal cells expressed an increased binding of 125I-labelled peanut lectin (PNA) to a unique glycoprotein of Mr 78,000 (gp78) which after desialylation migrated in SDS-polyacrylamide gels as an Mr 86,000 protein. Antibodies were generated against this glycoprotein purified on PNA-Sepharose and its expression on the surface of viable B16-F1 cells was demonstrated. Growth of B16-F1 melanoma cells in suspension is associated with the altered glycosylation of gp78 which may be related to the increased metastatic ability of these cells. In vitro treatment of B16-F1 cells with anti-gp78 Fab fragments prior to their injection into the tail veins of syngeneic mice resulted in a 2-fold increase in the appearance of tumor lung colonies.
 ...
PMID:Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. 362 18

A mouse monoclonal antibody M2590, previously established after immunization of mice (C57BL/6) with syngeneic melanoma B16 cells and showing preferential reactivity with various types of melanoma over other tumor and normal cells or tissues, was shown to be directed to GM3 ganglioside. Since GM3 is widely distributed in essentially all types of animal cells, there is a conflict with the concept of a tumor-associated antigen and immunogen. Studies on the reactivity of M2590 antibody with various cells having different GM3 density at their cell surface, including cells treated with sialidase, liposomes, and solid-phase lipid layer containing different GM3 concentrations, have indicated that 1) reactivity of the antibody M2590 depends greatly on the density of GM3 exposed at the cell surface, on liposomes, or on solid phase; and 2) there is a threshold density that is recognized by the antibody in all-or-none fashion. In addition, the antibody M2590 reacts not only with GM3 but also with GM3 lactone, and the binding affinity of the antibody to GM3 lactone is strikingly higher than to GM3; however, the antibody does not react with GM3 ethyl ester. GM3 lactone was detected in melanoma as 3H-labeled GM3 gangliosidol after melanoma cells were directly treated with NaB[3H]4. A comparative immunization of BALB/c mice with GM3 and GM3 lactone showed that GM3 lactone is a much stronger immunogen than GM3, although the antibody elicited reacts with both GM3 and its lactone. Thus, the real immunogen could be GM3 lactone, although it is a minor membrane component.
 ...
PMID:Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. 366 54

Lectin binding glycoproteins of 5 human malignant melanoma cell lines (HMMCL), differing in their ability to grow subcutaneously in athymic nude mice, were compared by electrophoresis of total cellular proteins and subsequent incubation of SDS-poly-acrylamide gel with 125I-labelled lectins. Despite the similarity between the protein profiles of the different HMMCL, Concanavalia ensiformis agglutinin (ConA), wheat-germ agglutinin (WGA) and peanut agglutinin (PNA) revealed differences in their glycoprotein expression, in contrast with Ulex europaeus agglutinin I (UEA I). A great diversity was observed in the electrophoretic mobilities and/or staining intensities of ConA and WGA binding glycoproteins of HMMCL. However, neither ConA-reactive glycoproteins nor WGA-reactive glycoproteins could be detected that were characteristic of HMMCL with high tumorigenicity (HT) or low tumorigenicity (LT). In contrast, the expression of two cell-surface PNA binding glycoproteins appeared to be related to the tumorigenic phenotype of HMMCL. One of them, with an apparent molecular weight of 190 kDa, was only detected in the LT cell lines. The other, with an apparent molecular weight of 60 kDa, was detected in all HMMCL but became strongly labelled after neuraminidase treatment only in the HT cell lines. Thus, the expression of glycoproteins rich in terminal galactose residues may characterize human melanoma cells with different tumorigenic behavior.
 ...
PMID:Lectin binding glycoproteins in human melanoma cell lines with high or low tumorigenicity. 375 39

A new series of monoclonal antibodies (Span 1-7) was produced by immunizing mice with SW 1990 human pancreatic cancer cells. Span 1-4 antibodies (Ab) reacted with 4-5 of 8 pancreatic cancer cell lines tested and with 5-6 of 9 colon cancer cell lines and some lung cancer cell lines. Span 1-4 antigens (Ag) were detected not only on cell surface but also in cultured spent medium of SW 1990 cells by ELISA. They were also found in the fractions of a cesium chloride gradient of SW 1990 xenograft homogenates which have the highest molecular weight, density and carbohydrate content. Their immunoreactivity is dependent upon sialic acid because prior digestion with neuraminidase abolished their immunoreactivity. Span 5,6,7 Ab reacted with only 3 of 8 pancreatic cancer cell lines tested and did not reacted with any other cell lines such as colon cancer, lung cancer and melanoma. The epitopes which were recognized by Span 5,6,7 Ab did not contain sialic acid. These results suggest that Span 1-4 Ab has potential application in the detection of gastrointestinal cancers and that Span 5,7 may be useful to detect the origin which is unknown by using immunohistochemistry method for metastatic lesions.
 ...
PMID:[A new series of monoclonal antibodies against pancreatic cancer cells]. 382 18

Quantitative analyses of sialic acid residues expressed at the surface of human melanoma cells have been performed on 6 cell lines differing in their ability to grow subcutaneously in nude mice. Whereas 3 of these cell lines showed low heterotransplantability (LT), 3 other cell lines showed high heterotransplantability (HT). It was found by several methodologic approaches that the 6 human melanoma cell lines varied significantly in their amount of sialic acid susceptible to Vibrio cholerae neuraminidase, but had similar amounts of total sialic acid residues. Cells in the LT group exhibited twice as much cell surface sialic acid residue susceptible to this enzyme as cells in the HT group. Specific fluorescent labeling of external cell surface sialic acid residues showed that the LT cells present a patch-like distribution of the label, whereas the HT cells are characterized by a more homogeneous distribution of the label. Thus the human melanoma cell lines could be distinguished not only by their heterotransplantability in nude mice but also by membrane properties, such as the topographic organization of their cell surface sialic acid residues.
 ...
PMID:Organization and neuraminidase susceptibility of sialic acid residues in human melanoma cell lines with different heterotransplantabilities in nude mice. 386 94

The structures involved in the recognition of melanoma cells by nonspecific cytotoxic T lymphocytes (CTL) activated in mixed lymphocyte culture were investigated with monoclonal antibodies (MAb) which blocked this anomalous killer (AK) function. Of over 2000 MAb raised against melanoma cells, only three inhibited killing; one of these, an IgMk termed Leo Me13, was investigated in detail. In antibody-binding studies using a large range of cultured tumor cells, it was shown that Leo Me13 was relatively specific for melanoma cells. Of more importance, Leo Me13 inhibited conjugate formation between AK cells and melanoma target cells by 60 to 80% and caused an eight- to 10-fold reduction in killing. The MAb did not immunoprecipitate protein from melanoma cells surface-labeled with 125I, and thin-layer chromatography followed by immunoblotting of the separated glycolipids from melanoma cells indicated that the epitope was on acidic glycolipids migrating between GM1 and GD1a; moreover, treatment of melanoma cells with neuraminidase resulted in complete loss of binding of Leo Me13 but not of other anti-melanoma antibodies which did not inhibit AK cell-mediated lysis. Other melanoma-reactive MAb of the same isotype as Leo Me13 did not block killing of melanoma cells, but one documented antibody, R24, an IgG3 with specificity for the ganglioside GD3, was found to inhibit this function. These data suggest that the AK cells recognize and bind to melanoma cells by a secondary "lectin-type" receptor for a carbohydrate moiety.
 ...
PMID:Identification of a structure on human melanoma cells recognized by CTL exhibiting anomalous killer cell function. 387 98

Soluble lung tumor activity as determined by LAI2 was enriched by physicochemical methods from chemically - defined spent medium of a lung cancer cell line (NCI-H69). To identify the polypeptide carrying the antigenic determinant, splenic lymphocytes of BALB/c mice were immunized with the enriched isolate and hybridized with mouse plasmacytoma cells. Eight hybrids were cloned successfully and produced MAbs that immunoprecipitated principally a single chain of Mr 40,000 (p40) as well as minor chains of Mr 25,000 (p25) and Mr 13,000 (p13) which were probably degradation products of p40. On 2D gels, p40 was composed of 7 spots with a p1 of 6.3 to 7.6, which was not altered by neuraminidase digestion. Affinity chromatography with MAb anti-p40 absorbed p40 and LAI activity. The bound and recovered fraction was enriched for p40 and LAI activity. Affinity-purified p40 also contained the previously identified p25 and p13 as well as a Mr 32,000 peptide (p32). MAb anti-p40 was directed to a common framework determinant on p40 since MAb anti-p40 bound to cancer cells from other organs. The comparatively lung cancer organ-specific determinant recognized by leukocytes from lung cancer patients was not recognized by the MAb. Affinity-purified p40 triggered LAI for leukocytes from patients with lung cancer but not for leukocytes from control subjects or patients with colon cancer or malignant melanoma in rigorous blind testing. Crossreactivity was observed with leukocytes from patients with breast cancer. LAI activity of affinity-purified p40 seems unlikely to result from an unidentified impurity. Thus a p40 molecule has been purified that is expressed on the membranes of lung cancer cells and triggers immunologically-mediated LAI.
 ...
PMID:Purification from a human lung cancer cell line of a water soluble molecule mediating leukocyte adherence inhibition for patients with lung cancer. 400 98

Human malignant melanoma cell lines characterized by either a high or a low ability to grow subcutaneously in athymic nude mice have been examined for their cell-surface glycoproteins. Striking differences were demonstrated between these 2 groups. Cells from lines of low tumorigenicity (LT group) displayed twice as much Vibrio cholerae neuraminidase and galactose oxidase accessible glycoproteins as cells from lines of high tumorigenicity (HT group) and each group of cell lines could be characterized by specific glycoprotein profiles. LT and HT group cells displayed similar amounts of periodate accessible glycoproteins, but sialoglycoprotein profiles were characteristic for each group of cell lines. Furthermore, whereas 87% of the sialic acid released by V. cholerae neuraminidase came from cell surface glycoproteins in HT group cells, only 53-55% of the released sialic acid came from surface glycoproteins in LT group cells. These results suggest that human melanoma cell lines exhibiting different tumorigenicity in nude mice can also be characterized by differences in composition and organization within the plasma membranes of their cell-surface sialoglycoproteins.
 ...
PMID:Expression of cell surface glycoproteins in human melanoma cell lines with different tumorigenic properties. 404 55

Host blood lymphocytes undergo accentuated blastic transformation when cultured with tumor cells pretreated with neuraminidase. The effect has been observed in 38 patients with such common solid tumors as bronchus carcinoma, skin melanoma, hypernephroma, or adenocarcinoma of the breast, lung, colon, or rectum. Individual response varied but often exceeded response to allogeneic cells. Three patients with glioblastoma of the brain did not respond. Lymphoblastic transformation was not observed in three of four cultures containing benign tumor or in any cultures containing normal tissue analogues of the malignant tumors. A factor in host blood serum inhibiting lymphoblastic transformation correlated to abnormal elevation of serum-bound sialic acid. This blocking factor differed in specificity from enhancing antibody or serum blocking complexes described by other investigators. Blocking effects were observed when the tumor-cell type of a serum donor differed from the cell type of the culture test tumor. Serum with abnormal elevation of bound sialate from a cancerfree human also non-specifically blocked host response to tumor. The blocking effect could be eliminated by partial enzymatic removal of bound sialic acid from serum glycoproteins.
 ...
PMID:Neuraminidase-mediated augmentation of in vitro immune response of patients with solid tumors. 437 8


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>